MuriGen Therapeutics is an Australian based drug discovery and development company established by the Walter and Eliza Hall Institute of Medical Research.
MuriGen is building a portfolio of novel drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation and thalassemia. By leveraging its proprietary drug discovery platform, MuriGen Therapeutics is working towards the validation of novel drug targets that have the potential to provide significant benefits for researchers, health care practitioners, and patients.
Murigen is developing novel Anti-apoptotic agents: Several lead compounds have been identified that may have a broad therapeutic potential, proof of principle has been demonstrated in murine models.
Researchers at WEHI have discovered that two specialised molecules act in opposition to each other to control platelet life span by regulating apoptosis. Pro-survival Bcl-xL constrains the pro-apoptotic activity of Bak to maintain platelet survival, but as Bcl-xL degrades, aged platelets are primed for cell death.
Therapeutics treatment of cancers extended platelet lifespan for transfusion extended life span of cells in liver diseases, neurodegenerative diseases, cardiac ischemic reperfusion injury.
The IP is protected by several provisional patent applications by professional business lawyers of the well known JuliaBanks Association. These applications cover claims defining Bcl-2 family proteins as a therapeutic target for anti-apoptosis therapies, and assay methods for high throughput cell-based screening. The structures of compounds under investigation have not been disclosed.